| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Copenhagen MS Center, Department of Neurology (Dr. Sorensen), and Institute for Inflammation Research (Drs. Ross and Bendtzen), Copenhagen University Hospital, Rigshospitalet; and Department of Neurology, Aalborg Hospital, and The Danish MS Treatment Register (Dr. Koch-Henriksen), Denmark.
* To whom correspondence should be addressed. E-mail: pss{at}rh.dk.
Abstract-- Background: Neutralizing antibodies (NABs) occur frequently in patients receiving interferon (IFN)-beta for multiple sclerosis (MS), but it is unclear whether occurrence of NABs is predictive for the persistence of NABs during continued IFN-beta therapy. Methods: The authors used an antiviral neutralization bioassay to measure NABs blindly from 6 months up to 78 months in patients with MS who were followed for at least 24 months during treatment with IFN-beta. Patients were classified into three groups: 1) persistently NAB-negative patients, defined as patients without any positive samples at any time; 2) definitely NAB-positive patients, defined as patients who had at least two consecutive positive samples; and 3) patients with fluctuating NAB-positive and NAB-negative samples. Results: A total of 455 patients were included in the study. Overall, 52.3% of the patients were persistently NAB-negative, 40.9% became definitely NAB-positive, and the remaining 6.8% were fluctuating. More patients treated with IFN-beta-1a (Avonex) remained NAB-negative (p < 0.0001), whereas there was no difference between IFN-beta-1b (Betaferon) and IFN-beta-1a (Rebif). Patients who have remained NAB-negative during the first 24 months of therapy rarely developed NABs. On the contrary, the majority of patients, who had been NAB-positive from 12 through 30 months after start of therapy, remained NAB-positive. Conclusions: NABs should be measured in all patients treated with IFN-beta. If patients have been persistently NAB-negative for 24 months, measurements can be discontinued. Patients who have been NAB-positive for a period of 18 months or more usually remain NAB-positive for a long time.
This article has been cited by other articles:
|
|
 |
|
  A. R. Pachner, D. Cadavid, L. Wolansky, and J. Skurnick Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study Neurology, November 3, 2009; 73(18): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Pachner, J. D. Warth, A. Pace, S. Goelz, and On behalf of the INSIGHT investigators Effect of neutralizing antibodies on biomarker responses to interferon beta: The INSIGHT study Neurology, November 3, 2009; 73(18): 1493 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hesse, F. Sellebjerg, and P. S. Sorensen Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity Neurology, August 4, 2009; 73(5): 372 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Millonig, D Rudzki, M Holzl, R Ehling, C Gneiss, B Kunz, T Berger, M Reindl, and F Deisenhammer High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study Multiple Sclerosis, August 1, 2009; 15(8): 977 - 983. [Abstract] [PDF]
|
|
|
|
|
|
N Koch-Henriksen, P. Sorensen, K Bendtzen, and E. Flachs The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, May 1, 2009; 15(5): 601 - 605. [Abstract] [PDF]
|
|
|
|
|
|
M Ravnborg, K Bendtzen, O Christensen, P. Jensen, D Hesse, M. Tovey, and P. Sorensen Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis Multiple Sclerosis, March 1, 2009; 15(3): 323 - 328. [Abstract] [PDF]
|
|
|
|
|
|
L. van der Voort, A Kok, A Visser, C. Oudejans, M Caldano, F Gilli, A Bertolotto, C. Polman, and J Killestein Interferon-{beta} bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice Multiple Sclerosis, February 1, 2009; 15(2): 212 - 218. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Soelberg Sorensen Review: Neutralizing antibodies against interferon-beta Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141. [Abstract] [PDF]
|
|
|
|
|
|
P. Sorensen, N Koch-Henriksen, E. Flachs, and K Bendtzen Is the treatment effect of IFN-{beta} restored after the disappearance of neutralizing antibodies? Multiple Sclerosis, July 1, 2008; 14(6): 837 - 842. [Abstract] [PDF]
|
|
|
|
|
|
R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF]
|
|
|
|
|
|
A.R. Pachner Neutralizing anti-IFN{beta} antibodies: clarity and confusion Multiple Sclerosis, November 1, 2007; 13(9): 1081 - 1082. [PDF]
|
|
|
|
|
|
C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137. [Abstract] [PDF]
|
|
|
|
|
|
A. R. Pachner and D. S. Goodin Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, October 9, 2007; 69(15): 1555 - 1556. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Calabresi, G. Giovannoni, C. Confavreux, S. L. Galetta, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, P. W. O'Connor, J. T. Phillips, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL Neurology, October 2, 2007; 69(14): 1391 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Ross Treatment strategies across the multiple sclerosis lifespan Neurology, June 12, 2007; 68(24_suppl_4): S1 - S2. [Full Text] [PDF]
|
|
|
|
|
|
A. Noronha Neutralizing antibodies to interferon Neurology, June 12, 2007; 68(24_suppl_4): S16 - S22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]
|
|
|
|
|
|
J. Oger Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions Multiple Sclerosis, May 1, 2007; 13(1_suppl): 5 - 7. [PDF]
|
|
|
|
|
|
F. Blanchette Clinical significance of glatiramer acetate antibodies Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35. [Abstract] [PDF]
|
|
|
|
|
|
J. Oger and E. Gibbs Binding antibodies: Vancouver's perspective Multiple Sclerosis, May 1, 2007; 13(1_suppl): 36 - 43. [Abstract] [PDF]
|
|
|
|
|
|
F. Deisenhammer Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-{beta} therapy Multiple Sclerosis, May 1, 2007; 13(1_suppl): 44 - 48. [Abstract] [PDF]
|
|
|
|
|
|
A.T. Reder Neutralizing antibodies in multiple sclerosis: a complex impact on interferon responses, magnetic resonance imaging findings and clinical outcomes Multiple Sclerosis, May 1, 2007; 13(1_suppl): 53 - 62. [Abstract] [PDF]
|
|
|
|
|
|
D. S. Goodin, E. M. Frohman, B. Hurwitz, P. W. O'Connor, J. J. Oger, A. T. Reder, and J. C. Stevens Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology, March 27, 2007; 68(13): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Sominanda, U Rot, M Suoniemi, F Deisenhammer, J Hillert, and A Fogdell-Hahn Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity Multiple Sclerosis, March 1, 2007; 13(2): 208 - 214. [Abstract] [PDF]
|
|
|
|
|
|
C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]
|
|
|
|
|
|
C. H Polman, J. Killestein, and H. Schellekens Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have? Multiple Sclerosis, June 1, 2006; 12(3): 245 - 246. [PDF]
|
|
|
|
|
|
B. Petersen, K. Bendtzen, N. Koch-Henriksen, M. Ravnborg, C. Ross, P. S. Sorensen, and The Danish Multiple Sclerosis Group Persistence of neutralizing antibodies after discontinuation of IFN{beta} therapy in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2006; 12(3): 247 - 252. [Abstract] [PDF]
|
|
|
|
|
|
P. S. Sorensen, N. Koch-Henriksen, M. Ravnborg, J. L. Frederiksen, K a. Jensen, A. Heltberg, H. Schaldemose, S. Deth, O l. Kristensen, M. Worm, et al. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey Multiple Sclerosis, June 1, 2006; 12(3): 253 - 264. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al. Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations Arch Neurol, October 1, 2005; 62(10): 1519 - 1530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Giovannoni and A. Goodman Neutralizing anti-IFN-{beta} antibodies: How much more evidence do we need to use them in practice? Neurology, July 12, 2005; 65(1): 6 - 8. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
